LD-2 disclosure · 2nd Quarter - Report
ALNYLAM PHARMACEUTICALS
Client
- Description
- Biopharmaceutical company
- Location
- Massachusetts · United States of America
Registrant
- Description
- Consulting
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesMedicare/Medicaid
Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas; Extension of Timeline for Final Rule Publication (CMS-1687-RCN). Provisions included in Subtitle J of H.R. 5376 - Build Back Better Act and Senate reconciliation bill. Issues related to access and coverage in Medicare Part D program.
LobbyistsJOHN MCMANUS · ALANNA TEMME
Covered position (JOHN MCMANUS): Staff Director W&M Health Subcommittee; LA, Rep. Bill Thomas
Covered position (ALANNA TEMME): LD, Rep. Jon Porter
TargetedSENATE · HOUSE OF REPRESENTATIVES
Health Issues
Inclusion of study on genetically targeted technologies in S. 4348 - FDASLA Act of 2022 and H.R. 7667 - Food and Drug Amendments of 2022.
LobbyistsJOHN MCMANUS · ALANNA TEMME
TargetedSENATE · HOUSE OF REPRESENTATIVES